Financial Report Outlook | BioNTech Q3

BioNTech will announce its Q3 results at 8 am EST on November 9th. On November 1, Pfizer raised its forecast for the full-year COVID-19 vaccine revenue in collaboration with BioNTech to US$36 billion.

In addition, BioNTech previously raised its full-year sales forecast in Q2 from 12.4 billion euros to 15.9 billion euros. The market expects that BioNtech will once again raise its annual revenue forecast for the new crown vaccine.

According to Bloomberg data, the market expects Q3 revenue to be close to 5 billion euros, with a gross profit margin of 82.9%, a decrease of 0.5% from the previous month; Q3 net profit is expected to be 2.588 billion euros, with a net profit margin of approximately 52%. However, it is worth mentioning that the performance of BioNTech's competitor Moderna Q3 fell short of market expectations.

At the same time, BioNTech outperformed Moderna in the past two quarters.

Net profit in 2021Q2 was 2.787 billion euros, compared with a loss of 88.3 million euros in the same period last year; net profit in the first half of 2021 was 3.915 billion euros (approximately US$4.5 billion).

According to Pfizer’s Q3 quarterly results, the company raised its forecast for full-year new crown vaccine revenue to 36 billion U.S. dollars, compared with 33.5 billion U.S. dollars previously expected.

Pfizer's new crown vaccine is also BNT162b2 in cooperation with BioNTech, which means that BioNTech may once again raise its annual new crown vaccine revenue forecast.